You are leaving the Blue Earth Therapeutics website. By clicking this link, you will be taken to a website that is independent from Blue Earth Therapeutics. The site you are linking to is not controlled or endorsed by Blue Earth Therapeutics and Blue Earth Therapeutics is not responsible for the content provided on that site.

ACCEPT
CANCEL

This page is intended for Healthcare Professionals only. Are you a Healthcare Professional?

Yes No

Blue Earth Therapeutics News

These media releases are intended for business/trade media.

2025
2024
2023
2022

NEWS FROM

30 October, 2024
Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies
READ MORE
08 October, 2024
Blue Earth Therapeutics Advances Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection with Promising Phase 1 Data
READ MORE
12 August, 2024
Blue Earth Therapeutics Ltd announces expansion of partnership with Seibersdorf Labor GmbH to include manufacture of therapeutic radiopharmaceutical, 225Ac-rhPSMA-10.1
READ MORE
23 July, 2024
Blue Earth Therapeutics Announces Clinical Research Collaboration with UCLto Develop Innovative Alpha-labelled Radioligand Therapy (RLT) for Prostate Cancer
READ MORE
08 April, 2024
FOR U.S. AUDIENCES ONLY Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer
READ MORE
28 February, 2024
FOR U.S. AUDIENCES ONLY Blue Earth Therapeutics Announces Participation in Upcoming B. Riley Securities Radiopharma Investor Conference
READ MORE
20 February, 2024
FOR US AUDIENCES ONLY Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer
READ MORE